January 28, 2022 The investigators from The Accelerated Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program, in collaboration with Drs. Chaim Putterman from the Albert Einstein College of Medicine and Chandra Mohan from the University of Houston, and the biotechnology company Equillium have discovered an immune pathway that plays an important role […] READ MORE
January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […] READ MORE
January, 2022 As of January, 2022, the U.S. Centers for Disease Control and Prevention (CDC) recommends the use of the vaccine Shingrix to prevent shingles and its complications in adults 19 years and older whose immune systems are weakened in addition to those adults 50 years and older whose immune systems are not compromised. Shingrix […] READ MORE
NEW YORK, NY, December 14, 2021. The Lupus Research Alliance proudly announced today recipients from the U.S. and around the world of the 2021 Lupus Innovation Award which will fund wide ranging areas of research from probing the development and progression of lupus to pointing to potential personalized therapies. The Lupus Innovation Award provides support […] READ MORE
December 9, 2021 People with lupus can be immunocompromised because of the disease itself or medications that suppress the immune system and some may not be adequately protected from COVID-19. A new treatment will soon be available for them. Evusheld was granted Emergency Use Authorization for COVID-19 prevention by the U.S. Food and Drug Administration […] READ MORE
December 9, 2021 The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia Pharmaceuticals from the AURORA 2 continuation study of Lupkynis™ (voclosporin). These results provide the longest available data for an FDA-approved medicine in lupus nephritis. The U.S. Food and Drug Administration approved Lupkynis arlier this year […] READ MORE
December 9, 2021 The Lupus Research Alliance (LRA) is proud and excited to partner again with the National Institutes of Health (NIH), the Foundation for the National Institutes of Health (FNIH), and others on a new program – Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) – that will apply new cutting-edge tools to […] READ MORE
New York, NY. November 23, 2021 – Last night’s Lupus Research Alliance (LRA) Breaking Through Gala was the most successful in the history of the organization raising $7.5 million – double that of any previous year — for lupus research. The hundreds attending the hybrid festivities in-person at the Ziegfeld Ballroom and online were inspired by […] READ MORE
November 22, 2021 The New York Jets and Lupus Research Alliance (LRA) hosted Lupus Awareness Day on November 21, 2021, at MetLife Stadium, with the Jets taking on their division rivals the Miami Dolphins. The event raised awareness of the devastating autoimmune disease and generated over $25,000 for lupus research. The check was accepted by […] READ MORE
This year the Lupus Research Alliance Breaking Through Gala will take place the evening of Monday, November 22, 2021 both in person and online! So whether you’ll be joining us in New York City at the Ziegfeld Ballroom or watching our live broadcast online, you can support the promising research that is breaking through the […] READ MORE
November 15, 2021 The Lupus Research Alliance (LRA) supports research into causes and mechanisms of lupus, and identification of targets supporting the development of new therapies or cures for lupus patients. At this year’s meeting of the American College of Rheumatology (ACR), 17 LRA-funded researchers presented their work to share discoveries with the thousands of […] READ MORE
November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […] READ MORE
